DelveInsight's Strategic Support to a Biopharma Leader in NSCLC Epidemiology Forecasting up to 2034, Segmented by Biomarker Types
In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company specializing in non-small cell lung cancer (NSCLC) turned to DelveInsight, a trusted name in healthcare analytics, for a comprehensive epidemiology forecasting analysis of NSCLC segmented by genetic biomarkers. With ambitious goals to refine their drug development strategy, pinpoint target patient populations, and streamline market access, the client faced complex challenges.
LAS VEGAS, April 24, 2025 /PRNewswire/ — DelveInsight's data-driven approach not only illuminated the path forward but also positioned the client as a frontrunner in biomarker-driven NSCLC therapies. This case study showcases how DelveInsight's expertise in epidemiology forecasting delivered actionable insights, driving strategic success in a competitive market.
Interested in getting the patient-based market forecasting report on the NSCLC market? Download sample
Challenges Faced by the Client in NSCLC Epidemiology Forecasting:
The client, a prominent player in oncology, sought to advance their pipeline of NSCLC therapies by leveraging precise epidemiological data. They required detailed biomarker-specific segmentation to strengthen their drug development strategy, accurately define target patient populations, and streamline market access planning. With biomarker-driven therapies becoming central to oncology, the client sought a comprehensive analysis of key genetic mutations and protein expressions, including PD-L1, KRAS, EGFR, BRAF, NTRK, MET, HER2, ROS1, and TIGIT.
They also needed granular, country-specific NSCLC epidemiological data forecasts across the 7MM: the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan, to evaluate regional patient trends and support commercial strategy development. The client requested long-term historical and forecast data spanning 2020 to 2034 to ensure alignment with clinical timelines and launch objectives. A core focus was uncovering opportunities in underexplored areas—specifically, rare biomarkers and difficult-to-treat gene fusions representing unmet needs in the current pharmaceutical landscape.
Explore detailed market insights, biomarker-driven epidemiology, and future forecasts – Click here to learn more.
DelveInsight's Strategic Methodology for NSCLC Epidemiology and Biomarker Forecasting
To help the client, DelveInsight adopted a multi-dimensional, data-driven approach to forecast the NSCLC epidemiology and its evolving biomarker landscape. This methodology integrated:
Real-World Evidence: Sourced from healthcare databases and patient registries.
Country-Specific Data: Leveraged cancer registries and regional health reports across the 7MM.
Scientific Literature: Analyzed peer-reviewed publications and meta-analysis clinical studies.
Primary Research: Conducted interviews with key opinion leaders (KOLs) to validate findings and capture nuanced insights. This robust data foundation enabled DelveInsight to build a dynamic epidemiology model tailored to NSCLC and its biomarker complexities.
Granular NSCLC Epidemiology Segmentation and Forecasting
As requested by the client, DelveInsight's analysis provided a comprehensive and granular perspective on the epidemiological landscape of non-small cell lung cancer across major markets. In 2024, the United States reported approximately 204K incident cases of NSCLC, with a higher incidence observed in men compared to women. A key trend was the high concentration of NSCLC cases in individuals aged 65 and older, highlighting the increasing impact of the disease on aging populations.
When assessing histological subtypes, adenocarcinoma remained the most common, accounting for approximately 59% of cases, followed by squamous cell carcinoma and large cell carcinoma.
A key focus of the analysis was biomarker-driven segmentation, which played a pivotal role in personalizing treatment approaches. PD-L1 emerged as the most prevalent biomarker, reaffirming its central role in guiding immunotherapy. Among genetic alterations, KRAS mutations were significant, and data on the populations of KRAS G12C mutations and non-G12C KRAS variants were presented to the client.
Other notable molecular alterations in NSCLC include:
EGFR and BRAF mutations – Each observed in a small but significant portion of cases
NTRK fusions – Found in a limited subset of patients
MET-related alterations – Including exon 14 skipping mutations, gene amplifications, and c-MET overexpression
Emerging biomarkers – Such as HER2 mutations/amplifications, ROS1 rearrangements, and TIGIT expression, all drawing growing interest in clinical research and targeted therapy development
The study also presented insights into stage-wise epidemiological distribution, offering strategic perspectives for therapeutic interventions. Early-stage NSCLC (Stages I & II) represented approximately 35% of diagnosed cases, indicating growing potential for adjuvant and neoadjuvant treatment approaches. Meanwhile, advanced-stage disease (Stages IIIB & IV) accounted for nearly 50%, aligning with the current focus of most targeted therapies and immunotherapy regimens.
DelveInsight's robust epidemiological segmentation enabled a deeper understanding of the NSCLC burden, unlocking opportunities for precision medicine, clinical development, and market strategy.
Custom Non-Small Cell Lung Cancer Evergreen Forecasting Model (2020–2034)
DelveInsight's Custom Forecast Model (2025-2034) provided the client with a dynamic, evergreen tool to navigate the rapidly evolving landscape of non-small cell lung cancer. This model projected NSCLC incidence trends while adjusting for a variety of influencing factors, ensuring the client had accurate insights for strategic decision-making.
Key Factors Influencing the Forecast:
Demographic Shifts: The model accounted for the aging population and changes in smoking prevalence, both of which significantly affect NSCLC incidence.
Advancements in Genetic Testing & Screening: With the increased adoption of biomarker testing across countries, the model projected how genetic advancements could impact disease identification and treatment.
Country-Specific Biomarker Testing Trends: The extent to which various countries have integrated or recommended biomarker testing played a crucial role in forecasting NSCLC trends.
Evolving Treatment Paradigms: The rapid introduction of new targeted therapies and immunotherapies reshaped treatment options, and the model accounted for these changes to provide forward-looking insights.
Strategic Impact & Key Insights
By leveraging DelveInsight's biomarker-driven epidemiology forecasting, the client gained essential insights that significantly influenced their strategic decisions:
Optimizing Clinical Trial Planning: The client was able to identify specific biomarker-driven patient populations as key targets for clinical trials, ensuring focused and efficient research efforts.
Strengthening Market Expansion Strategy: By prioritizing countries based on biomarker prevalence trends, the client was able to tailor their market entry strategy, enhancing the chances of success in select regions.
Enhancing Regulatory & Commercial Decision-Making: The detailed segmentation data supported discussions around label expansion, payer negotiations, and pricing strategies, providing a competitive edge in the market.
Impact & Results after DelveInsight's Help
Through DelveInsight's comprehensive NSCLC epidemiology study, the client saw tangible business value in several key areas:
Enhanced Drug Development Strategy: The company optimized patient enrollment criteria for its NSCLC biomarker-driven clinical trials, ensuring that research focused on the most relevant populations.
Informed Market Access Plans: The forecasting data helped shape targeted commercialization strategies for different geographies, allowing the client to enter high-opportunity markets more effectively.
Competitive Positioning: The client gained a first-mover advantage in biomarker-driven NSCLC therapies, positioning themselves as leaders in the evolving precision oncology market.
According to DelveInsight's NSCLC market report, the value of the NSCLC market in the 7MM was approximately USD 30 billion in 2024, with substantial growth projected through 2034. The treatment landscape is evolving rapidly, led by biomarker-driven therapies and the rising adoption of PD-L1-targeting immunotherapies. Merck's KEYTRUDA has emerged as the gold standard for first-line treatment, particularly when combined with platinum-based chemotherapy for patients without actionable mutations.
Leading companies are leveraging DelveInsight's biomarker-specific epidemiology forecasting to gain deep insights into disease segmentation, long-term incidence trends, and biomarker prevalence. These insights enable companies to refine their R&D and commercialization strategies, driving data-driven decisions for better patient outcomes and sustained market growth.
Key players in the NSCLC market include AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, GSK, Gilead Sciences, BieGene, Nuvalent, and emerging biotechs like Nuvalent, Moderna, and BeiGene, with pipelines targeting KRAS, MET, EGFR, NTRK, TIGIT, and more.
Driving Business Success through DelnveInsight's Data-Driven Insights
DelveInsight's NSCLC biomarker-driven epidemiology forecasting empowered the client to navigate a complex and competitive market confidently. With granular, actionable insights, DelveInsight not only refined the client's drug development and commercialization strategies but also positioned them as a leader in precision oncology.
This case study highlights how DelveInsight's data-driven foresight transformed challenges into strategic opportunities, driving both business success and improved patient outcomes in the NSCLC market. DelveInsight continues to lead the way in offering innovative solutions, providing a range of services that empower clients to make informed decisions in the ever-evolving healthcare landscape.
Here are some of the other key services that DelveInsight excels in and pioneers:
Competitive Intelligence Services Tailored to Oncology Domain: DelveInsight's competitive intelligence services deliver real-time, precise insights across therapeutic domains, with oncology being one of our key areas of expertise. We provide in-depth analysis of advancements across both prevalent and rare conditions, including NSCLC, Pancreatic Cancer, Breast Cancer, and Acute Myeloid Leukemia, among others. Our services track competitor pipelines, clinical trial progress, regulatory shifts, and patent landscapes, offering a comprehensive view of the evolving oncology market. By leveraging these insights, stakeholders can identify emerging threats, seize growth opportunities, and craft strategic moves to stay ahead in this dynamic space.
Market Size and Share Assessment Services: DelveInsight provides a 360-degree market landscape analysis, delivering 10-year epidemiology-driven market forecasts. Our expertise offers precise insights into emerging therapies' current and projected market share, helping stakeholders navigate evolving treatment landscapes. By integrating emerging trends, competitive dynamics, and unmet needs, we empower businesses to craft data-driven strategies and identify lucrative opportunities. Whether it's pipeline analysis, pricing strategies, or competitive benchmarking, DelveInsight delivers actionable intelligence tailored to your strategic goals.
R&D Analysis: DelveInsight's skilled research and development analyst specializes in the complexities of different indications, offering essential insights and advice to clients aiming to advance in research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each drug in both pre-clinical and clinical stages. DelveInsight's comprehensive reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence.
Portfolio Management: DelveInsight's Portfolio Management services help clients assess competencies, leverage strengths, and align strategic priorities. Our structured approach identifies market needs, optimizes resources, and enhances portfolio value. With comprehensive market intelligence, we empower organizations to make informed, data-driven decisions, minimizing risks and maximizing long-term impact for both customers and the company.
Why Choose DelveInsight?
DelveInsight's Market Assessment Services provide data-driven insights and competitive intelligence to help pharmaceutical companies navigate evolving market landscapes. With 10-year forecasts, drug uptake analysis, competitive benchmarking, and customized market evaluations, we deliver precise projections for both emerging and established markets. Our expertise in epidemiology modeling, primary intelligence, and data analytics ensures clients gain a clear, strategic understanding of their therapy's potential and competitive positioning. Covering the 7MM region and beyond, DelveInsight equips stakeholders with actionable intelligence to drive informed decision-making and commercial success.
Get in touch today to leverage our expertise and stay ahead in the competitive market! Contact us for a personalized consultation.
Contact UsShruti Thakurinfo@delveinsight.com+1(469)945-7679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/a-success-story–delveinsights-strategic-support-to-a-biopharma-leader-in-nsclc-epidemiology-forecasting-up-to-2034-segmented-by-biomarker-types-302437159.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
123Invent Inventor Develops Improved Bra for Curvier Women
PITTSBURGH, June 9, 2025 /PRNewswire/ — 'As a curvier woman, I hated the discomfort associated with wearing a traditional bra. I wanted to create a more comfortable option for me, my daughter, and other women with curves,' said an inventor, from Wagga, NSW, Australia, 'so I invented the CroBra (by Char). My design provides added comfort and support, and the improved sizing guide helps you select the right size.' The patent-pending invention provides an improved bra option for curvier women. In doing so, it prevents the bra from riding up and digging into the skin. It also helps prevent bulging. As a result, it increases comfort and support. Additionally, the invention features a unique design that is easy to wear. The CroBra (by Char) is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Lidia Ilievski at 045-720-0678 or email info@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
FirstEnergy Announces Proposed Offering of $950 Million of Convertible Senior Notes Due 2029 and $850 Million of Convertible Senior Notes Due 2031
AKRON, Ohio, June 9, 2025 /PRNewswire/ — FirstEnergy Corp. (NYSE: FE) ('FirstEnergy') announced today that it intends to offer, subject to market and other conditions, $950 million aggregate principal amount of convertible senior notes due 2029 (such series, the '2029 Notes') and $850 million aggregate principal amount of convertible senior notes due 2031 (such series, the '2031 Notes' and, together with the 2029 Notes, the 'Notes') in a private placement under the Securities Act of 1933, as amended (the 'Securities Act'). FirstEnergy also intends to grant to each of the initial purchasers of the Notes an option to purchase, within a 13-day period from, and including, the date on which the convertible notes are first issued, up to an additional $150 million aggregate principal amount of the 2029 Notes and an additional $150 million aggregate principal amount of the 2031 Notes. FirstEnergy intends to use the net proceeds from the offering of the Notes for (i) the repurchase of all or a portion of the $1.5 billion aggregate principal amount outstanding of its 4.00% convertible senior notes due May 1, 2026, (ii) the repayment, redemption or refinancing of existing indebtedness, (iii) general corporate purposes, or (iv) any combination of the foregoing. FirstEnergy's management will have broad discretion in determining how the net proceeds from the offering will be used. The Notes will be unsecured and unsubordinated obligations of FirstEnergy, and will be convertible at the option of the holders of each series of Notes upon satisfaction of certain conditions and during certain periods. Interest will be payable semiannually in arrears. FirstEnergy will settle conversions of the Notes by paying cash up to the aggregate principal amount of the convertible notes to be converted and paying or delivering, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The interest rate, initial conversion rate and other terms of each series of Notes will be determined at the pricing of the offering. The offering is being made to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. Any offers of the Notes will be made only by means of a private offering memorandum. None of the Notes or any shares of the common stock issuable upon conversion of the Notes have been or are expected to be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any shares of common stock issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About FirstEnergy Corp. FirstEnergy is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation's largest investor-owned electric systems, serving more than 6 million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company's transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy online at and on X @FirstEnergyCorp. Forward-Looking Statements: This news release includes forward-looking statements based on information currently available to management and unless the context requires otherwise, references to 'we,' 'us,' 'our' and 'FirstEnergy' refers to FirstEnergy Corp. and its subsidiaries. Such statements are subject to certain risks and uncertainties and readers are cautioned not to place undue reliance on these forward-looking statements. These statements typically contain, but are not limited to, the terms 'anticipate,' 'potential,' 'expect,' 'forecast,' 'target,' 'will,' 'intend,' 'believe,' 'project,' 'estimate,' 'plan' and similar words. These statements include declarations regarding management's intents, beliefs and current expectations, including statements regarding FirstEnergy Corp.'s current expectations and beliefs as to the pricing and closing of the convertible notes offering and use of the proceeds thereof. These forward-looking statements are not guarantees of future performance and they are based on management's expectations that involve or rely on a number of known and unknown risks, uncertainties and other factors that are difficult to predict or are beyond our control, and reflect management's beliefs and assumptions based on information available at the time the statements are made. FirstEnergy Corp. cautions you that actual results may differ materially from those expressed, implied or forecast by the forward-looking statements. Risks that may cause these forward-looking statements to be inaccurate or incorrect include, among others whether we will be able to consummate the convertible notes offering; the final terms of the convertible notes offering; the satisfaction of customary closing conditions with respect to the convertible notes offering; prevailing market conditions; the anticipated use of net proceeds of the convertible notes offering which could change as a result of market conditions or for other reasons; and the risks and other factors discussed from time to time in our Securities and Exchange Commission filings, including, but not limited to, the most recent Annual Report on Form 10-K, and any subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. FirstEnergy Corp. expressly disclaims any obligation to update or revise, except as required by law, any forward-looking statements contained herein or in the information incorporated by reference as a result of new information, future events or otherwise.
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Newlyweds Say 'I Do' to Love, But 'I Don't' to Estate Planning: 42% of Couples Haven't Created One
New Survey from Trust & Will Finds Marriage Sparks Conversations About Legacy—But Many Delay Estate Planning for a Decade or More SAN DIEGO, June 9, 2025 /PRNewswire/ — Love is in the air this wedding season, but financial protection isn't. A new report from Trust & Will exposes a critical disconnect between love, life milestones, and long-term planning. Despite saying 'till death do us part,' 42% of married Americans have no estate plan whatsoever – leaving their spouses and families financially vulnerable. With over two million weddings expected for 2025 – with 225,000 expected in June alone and well over 600,000 in summer1 – the timing couldn't be more critical. Yet, the survey reveals that even marriage, one of life's most significant milestones, fails to prompt immediate action on estate planning. 'When I got married, my wife and I realized we had no will, no healthcare directive, nothing. It was a wake-up call,' said Cody Barbo, Co-founder and CEO of Trust & Will. 'That realization inspired the very foundation of this company. Marriage is about building a life together, and an estate plan is part of securing that life.' The national survey of 750 Americans (evenly split among single, engaged, and married respondents) uncovered deep gaps in awareness, confidence, and estate planning behavior. The Procrastination Problem: While married individuals are nearly 4x more likely than engaged couples to have a will (44% vs. 12%), nearly half still have no estate plan at all. Of those who do plan, 30% waited 9 years or more after marriage to act; 38% of engaged respondents say marriage motivated them to consider estate planning. Only 19% of married couples create an estate plan within their first four years together. Overcoming the Engagement Disconnect: 38% of engaged couples say marriage motivates them to consider estate planning, but only 12% actually have a will. 50% admit they lack basic estate planning knowledge. Only 15% have a healthcare directive, and 9% don't know what one is. 37% haven't even considered naming an executor or trustee for their estate. The Gender and Generational Divide Millennials and Gen Z show strong intent (40%+ plan to create estate plans within 5 years) but they face barriers like cost, time, and lack of understanding. Men are 3x more likely to have a trust than women. Women are more likely to feel overwhelmed by estate planning and 38% more likely to feel financially insecure. Despite 67% of respondents citing 'being overwhelmed' as their primary barrier, estate planning can be completed in hours. Without planning, surviving spouses can face: A lengthy and expensive probate process. Inability to make critical medical decisions. Freezing of financial accounts. Disputes among family members over assets. Potential tax issues. 'A wedding is more than a celebration, it's a pledge to protect one another,' said Barbo. 'Creating an estate plan is one of the most meaningful expressions of love. It offers your partner peace of mind, security, and the clarity that comes from knowing your wishes are understood and honored.' To read the full report, please visit: About Trust & WillFounded in 2017, Trust & Will is the leading digital estate planning platform in the U.S., trusted by over one million individuals and families. Our simple, secure, and attorney-approved online solutions help Americans easily create wills, trusts, healthcare directives, and other essential estate planning documents tailored to state-specific laws. With a focus on easy access and a guided experience, we're transforming how families plan for the future and protect their legacies. Our platform supports 20,000+ financial advisors, along with 150+ enterprise partners and financial institutions — including AARP, Fifth Third Bank, LPL Financial, UBS, and USAA. We empower professionals to integrate estate planning into their client services, enabling multi-generational wealth planning. With more than one million users and $100+ billion in self-reported estate assets, Trust & Will is redefining estate planning as a relationship-deepening driver of financial wellness. Recognized for innovation and leadership, Trust & Will has earned spots on the CNBC Disruptor 50, Inc. 5000, and Deloitte Technology Fast 500™ lists. Learn more at Media Contact: Mark LoCastro, Trust & Willpress@ 1 'Here Comes … A Lot of Couples Getting Married,' National Jeweler, June 29, 2022 [source URL]
